Healix

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population

Presented on October 4, 2017

Authors:
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc., Sugar Land, TX
Richard M. Mandel, MD, FIDSA – University of Arizona College of Medicine, Tucson, AZ
Ramesh V. Nathan, MD, FIDSA – Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
Andrew H. Krinsky, MD – Infectious Diseases Associates, Sarasota, FL
Quyen Luu, MD – Quyen Luu Central Georgia Infectious Diseases, Macon, GA
Alfred E. Bacon, III, MD – Infectious Disease Associates PA, Newark, DE
H. Barry Baker, MD, FACP – Infectious Disease Physicians, Miami, FL
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Inc., Sugar Land, TX
Kimberly A. Couch, PharmD, MA, FIDSA, FASHP – Healix Infusion Therapy, Inc., Sugar Land, TX

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound